naftopidil
Sign in to saveNaftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hyperplasia which acts as a selective α1-adrenergic receptor antagonist or alpha-1 blocker.
Research
317 papers- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2018
- Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.Current medical research and opinion · 2014
- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2009
- Drug Repositioning of the α(1)-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug?International journal of molecular sciences · 2020
- Naftopidil reduced the proliferation of lung fibroblasts and bleomycin-induced lung fibrosis in mice.Journal of cellular and molecular medicine · 2019
via PubMed
~1 min read
Encyclopedic overview
3 sectionsContents
- Synthesis
- See also
- References
Naftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hyperplasia which acts as a selective α1-adrenergic receptor antagonist or alpha-1 blocker.
==Synthesis== upright=2|class=skin-invert-image
Excerpted from Wikipedia’s “naftopidil” article, available under the CC BY-SA 4.0 licence.